Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154

Inclusion Criteria: * Male or female ≥18 years of age on the day of signed informed consent. At least 8 subjects of each sex will be enrolled. * Currently receiving anticoagulant therapy at the permitted therapeutic dose as described below, and who have been on the same anticoagulant for ≥30 days prior to Screening Permitted anticoagulants and doses include: Warfarin, any dose as prescribed as long as the International Normalized Ratio (INR) criteria are met; apixaban (Eliquis®), 10 mg total daily dose; or rivaroxaban (Xarelto®), ≥15 mg total daily dose * Subjects on Warfarin must meet INR therapeutic range: INR 2-3.5 * Willing and able to provide informed consent prior to any study procedures and to comply with all aspects of the protocol Exclusion Criteria: * Allergy or sensitization to any components of BXP154 * Known genetic/familial hypercoagulable disorder * Thrombocytopenia (platelets \<75,000/mm3) * Subjects using any prescribed chronic drug therapies that impact platelet function including clopidogrel (Plavix®), prasugrel (Effient®), ticagrelor (Brillinta®), dipyridamole (Aggrenox®), cilostazol (Pletal®), aspirin, or any non-steroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen, naproxen, diclofenac, indomethacin, ketorolac, etc.) are excluded from participation in the study. NSAIDs or aspirin taken on an as needed (PRN) basis must be discontinued according to the following required windows prior to Day 1 (aspirin, 7 days; ibuprofen, 24 hours; all other NSAID…